Intestinal glycosphingolipid receptor (GSL)

Intestinal glycosphingolipids (GSLs) are essential components of the plasma membrane of intestinal epithelial cells, consisting of a hydrophobic ceramide lipid tail and a hydrophilic complex carbohydrate head group. These molecules are predominantly localized within lipid rafts on the apical membrane, where they contribute to the structural integrity of the brush border and participate in vital cell signaling and recognition processes (Lingwood, 2011). In the context of human disease, GSLs are most notable for acting as high-affinity receptors for a variety of bacterial toxins and viral pathogens; for example, the ganglioside GM1 is the primary receptor for the Cholera toxin, while globotriaosylceramide (Gb3) is the receptor for Shiga toxins (Sandvig et al., 2004). Therapeutic strategies targeting these molecules often involve substrate reduction therapy (SRT) to decrease their synthesis or the use of decoys to prevent pathogen attachment. Drugs like Miglustat and Eliglustat, which inhibit glucosylceramide synthase, are used to manage lysosomal storage diseases by reducing GSL accumulation, though they also impact the GSL profile of the intestinal epithelium (Cox et al., 2000). Understanding the distribution and function of these lipids is crucial for developing treatments against enteric infections and metabolic disorders.

Other names

Intestinal glycosphingolipidEpithelial glycosphingolipidGanglioside receptorNeutral glycosphingolipidGlycosphingolipids on epithelial membranes

Inhibition of glucosylceramide synthase to reduce glycosphingolipid levels; competitive inhibition of pathogen or toxin binding to the carbohydrate head group.